Hypertrophic cardiomyopathy (HCM) has been associated with sudden death in young athletes. On long-term follow up, syncope, chest pain and dyspnea are well known frequent symptoms due to the dynamic left ventricular outflow tract (LVOT) obstruction, mitral regurgitation and diastolic dysfunction. To reduce the LVOT pressure gradient, septal myectomy and alcohol injection have recently been utilized. However, some complications have been reported with alcohol ablation of the septal branches, such as complete atrioventricular block and alcohol spill over to ablate the entire left anterior descending coronary artery. Herein, a case of coil embolization of the septal branches, with successful reduction of the LVOT pressure gradient, is reported in a patient with HOCM. 
Introduction
Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, typically of a nondilated chamber, without an obvious cause, such as aortic stenosis or systemic hypertension. Syncope, chest pain and dyspnea are well known frequent symptoms due to the dynamic LVOT obstruction, mitral regurgitation and diastolic dysfunction. To reduce the LVOT pressure gradient, septal myectomy and alcohol injection have recently been utilized. The induction of a limited therapeutic infarction, through alcohol ablation of the septal branch, leads to a reduction of the LVOT pressure gradients and associated symptoms. However, some complications have been reported with alcohol ablation of the septal branches, such as complete atrioventricular block and inadvertent spillage of alcohol into a non-target vessel. Herein, a case of coil embolization of septal branches, with successful reduction of LVOT pressure gradient, is reported in a patient with hypertrophic obstructive cardiomyopathy (HOCM).
Case
A 57-year-old man was referred to our hospital with a history of fainting and a systolic murmur about 3 years ago. He had history of presyncope and symptoms of chest pain and dyspnea on exertion. He had smoked half a pack per day for 40 years. On physical examination, a grade 3/6 mid-systolic murmur was present at the left sternal border and cardiac apex. Echocardiography showed diffuse asymmetric septal hypertrophy and systolic anterior motion (SAM) of the chordae tendinae with flow acceleration at the mid-ventricular level during Valsalva maneuver (peak velocity: 2.9 m/sec). At first, 25 mg of atenolol, twice per day, was prescribed and the patient managed relatively well during his daily life. 
Discussion
Hypertrophic cardiomyopathy (HCM) is a common genetic abnormality that can occur in as many as 1 in 500 persons.
1) The cardinal feature is inappropriate myocardial hypertrophy, with no obvious cause of the hypertrophy (e.g. aortic stenosis or systemic hypertension), frequently with asymmetrical involvement of the septum, accompanied by a hyperdynamic systolic function. Medically, beta blockers and other negative inotropic drugs, such as verapamil and disopyramide, can reduce the LVOT obstruction and diminish the symptoms.
5)6)
In some patients, medical therapy ultimately proves insufficient for control of the symptoms. A myectomy for symptomatic HOCM that is unresponsive to medical therapy has been successfully carried out for more than three decades.
3) The procedure consists of excising a portion of the hypertrophied septum, mobilization of the papillary muscles and readaptation of the mitral valve subvalvular apparatus. 5) The operative procedure is complicated by a high mortality rate of 1.6 to 10.0%, with the possibility of perioperative complications, such as the emergence of a ventricular septal defect, total atrioventricular block or cerebral embolism, particularly in connection with an intraoperative myectomy.
7)
The beneficial effects of a myectomy led to the concept of nonsurgical septal myocardial reduction therapy (NSRT).
5) The induction of a limited therapeutic infarction, through alcohol ablation of the septal branch, leads to a reduction in the LVOT pressure gradients and associated symptoms. 8) This is presumably due to a re- Chang et al 10) have recently reported that an LVOT gradient ≥25 mmHg after NSRT, in the catheterization laboratory, and a peak CK <1300 U/L were the only independent predictors of an unsatisfactory outcome. The number of injected arteries, the volume of ethanol injected and the speed of injection (bolus vs. slow injection) are associated with large infarcts. 11) In contrast,
Boekstegers et al 12) reported that small septal infarctions (mean CK 413±193 U/L) were sufficient to result in a sustained decrease in the LVOT obstruction and an improvement in the symptoms. The incidence of complications, such as complete heart block with necessary permanent pacemaker implantation, seems to diminish with minimization of the infarct size. To minimize the amount of ethanol required and, correspondingly, the size of the septal infarction, identification of the culprit septal branch appears to be crucially important. Recently, intra-procedural myocardial contrast echocardiography (MCE) has been suggested for defining the extent and localization of the induced septal necrosis more precisely than pressure guidance.
8)
The septal damage caused by 96% ethanol instillation, followed by myocardial shrinkage and scar formation, may potentially be arrhythmogenic and give rise to life threatening ventricular arrhythmias. 13) Baseline conduction abnormalities have been suggested as risks factor for the development of complete heart block. Female gender, number of injected septal arteries and bolus injection of ethanol may also contribute to the development of complete heart block. 14) With experience and technique modification, such as the use of myocardial contrast echocardiography and slow injection of alcohol, the incidence of complete heart block that requires a permanent pacemaker can be decreased. 14) Left or right ventricular free wall infarctions, due to inadvertent spillage of alcohol into a non-target vessel, have been reported. 6) To avoid several serious complications that can be induced by unintended alcohol spillage, the method of coil embolization for septal branch ablation was introduced by us. Coil embolization has been used to occlude the small vessels, such as an intracranial aneurysm, arteriovenous malformation and patent ductus arteriosus.
Coronary angiography was performed and the first and second septal branches ablated with coils. The pressure gradient across the LVOT was eliminated just after this procedure, after which the patient experienced a dramatic improvement in symptoms. The dramatic decrease in the LVOT pressure gradient after NSRT in the catheterization laboratory is a good prognostic factor. However, the peak CK level (316 IU/L) was relatively low, so the infarcted lesion may be expected to be small. The eliminated LVOT pressure gradient might have been caused by the myocardial contractile dysfunction induced by the septal infarction. Four months after the procedure, the patient remained free of symptoms, and the follow up echocardiography showed a mild persistent LVOT pressure gradient at rest (PG: 30 mmHg). Several limitations must be considered in this report. No myocardial contrast echocardiography was performed in this study, which may have been useful in identifying the target septal vessels. 8) One day after the coil embolization, a follow up echocardiography was performed, but no significant reduction in the pressure gradient was obtained, so verapamil and atenolol was prescribed to the patient, and maintained. Although the patient felt symptomatic improvement, septal branch ablation with a coil is considered a palliative and not a curative procedure in this case. A follow-up coronary angiography may be required to see if collateral vessels have developed, and if feasible, embolization of the third septal branch may be attempted after the contrast echocardiography. The possible advantage of coil embolization may be the absence of complications, such as complete AV block or alcohol spill over, which have frequently been reported in alcohol ablation.
So far, coil embolization of the septal branch has not been reported as effective in the treatment of hypertrophic obstructive cardiomyopathy, and more experiences and long-term follow-up data are required to determine the effectiveness of this therapy.
